The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

Sponsor
Eastern Hepatobiliary Surgery Hospital
Study ID
NCT07285850
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • HCC - Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD). The study aims to compare the efficacy differences between sequential therapy and concurrent therapy using bevacizumab and atezolizumab for advanced HCC in MASLD. The research will focus on evaluating objective response rates, progression-free survival, disease control rates, and overall survival, while utilizing biomarker analysis to elucidate treatment mechanisms. Additionally, the study will examine treatment safety, including the incidence and severity of adverse events.

Key Dates

Start date
Oct 20, 2025
Status verified
Dec 2025
Primary completion
Aug 30, 2026
Completion
Aug 30, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Sequential treatment of bevacizumab combined with atezolizumab (sequential group)
    Sequential treatment of bevacizumab combined with atezolizumab (sequential group)
  • Active Comparator: Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)
    Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Primary Outcome Measure

objective response rate (ORR) [ Time Frame: 6 Months ]

Central Contacts

Related Studies